- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05780931
Rehabilitating Vision Loss in Veterans With Age-Related Macular Degeneration (AMD)
Development of New Approaches to Rehabilitating Vision Loss in Veterans With Age-Related Macular Degeneration
This study will help develop new methods of rehabilitating Veterans with vision loss due to Age-related macular degeneration.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this research study is to develop new and improved methods of helping vision-impaired Veterans see better by using hands as "seeing eyes". This study will focus on Veterans with a common form of eye disease called age-related macular degeneration that affects older individuals.
Study Type
Contacts and Locations
Study Locations
-
-
Georgia
-
Augusta, Georgia, United States, 30904-6258
- Charlie Norwood VA Medical Center, Augusta, GA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Veterans with vision loss caused by age-related macular degeneration
Description
Inclusion Criteria:
- The subject is a Veteran
- The subject has best-corrected visual acuity (BCVA) of 20/40 or worse in each eye, as determined by the standard Charlie Norwood VA Medical Center (CNVAMC) optometric tests
- The subject has visual field deficit of 10O in either eye as determined by the Octopus 900 perimetry (Haag-Streit Diagnostics, Haag-Streit USA, Mason, OH) administered by CNVAMC. (When the deficit/s are binocular, they do not necessarily have to be in binocularly corresponding positions)
- The subject has received a formal clinical diagnosis of age-related macular degeneration (AMD) in one or both eyes (binocular AMD does not necessarily have to be in binocularly corresponding positions)
- The subject has visual deficit in either eye (wavy lines and/or missing/darkened areas on the grid) determined by the standard Amsler Grid Test
- The subject has not yet started any rehabilitative treatment for AMD-related vision loss
- Both eyes of the subject are otherwise age-appropriately stable, and neither eye has any other visual defects, as determined by the standard CNVAMC ophthalmological examination
- The subject must be able to understand the nature and individual consequences of the study
- The subject must be able to provide signed and dated informed consent before start of any participation in the study procedures (11)Women with childbearing potential must test negative for pregnancy using a standard urine test prior to participating in each functional magnetic resonance imaging (fMRI) procedure. (This exclusion criterion is mandated by the Augusta University Institutional Review Board [AU IRB], which also serves as the IRB of record of the CNVAMC. It is intended as an extra precautionary measure to help ensure the health and safety of this vulnerable population. The proposed study will comply with this requirement.)
Exclusion Criteria:
- According to the patient's VA clinical records, the patient has one or more clinically diagnosed neurological disorder
- According to the patient's VA clinical records, the patient has one or more clinically diagnosed cognitive deficits
- According to the patient's VA clinical records, the patient has been clinically diagnosed with a psychiatric disorder that would make it unduly uncomfortable or otherwise clinically inadvisable for the subject to participate in the study
- According to the patient's VA clinical records, according to the patient, or both, the patient has motor disorder/s that would make it unduly uncomfortable or otherwise clinically inadvisable for the subject to participate in the study
- According to the patient's VA clinical records, according to the patient, or both, the patient has an MR-incompatible implant and/or another condition (e.g., claustrophobia) that would make it inadvisable for the subject to participate in MR imaging or any other study procedure
- The patient does not understand the informed consent information and/or the standard study instructions in spoken or written English, and/or is unable to follow study instructions. [The purpose of this exclusion criterion, required by the AU IRB, is to help ensure that the subjects adequately understand all the information relevant to providing informed consent, as well as the study instructions.]
- Inability to give informed consent to participate in the study
- Pregnancy, as determined by a standard urine test for pregnancy
- Participation in other study/studies including an investigational drug or device during the present study
Study Plan
How is the study designed?
Design Details
- Observational Models: CASE_CONTROL
- Time Perspectives: PROSPECTIVE
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Treatment Group
This is the group of study subjects which will undergo study-related rehabilitation procedures. |
Study-specific rehabilitation procedures will systematically manipulated the spatial or temporal synchrony (or coordination) of visual vs. haptic inputs that the subjects receive.
Other Names:
|
|
Control Group
This is the group of study subjects which will undergo control (sham) rehabilitation procedures (in addition to all their regularly scheduled treatments and interventions). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Accuracy of object recognition
Time Frame: 6-10 weeks
|
This outcome will be measured as the accuracy (% correct) with which the study subjects recognize the text objects before, during and after their participation in the study procedures. |
6-10 weeks
|
|
Response of brain regions of interest (ROI) as reflected in the BOLD (blood oxygenation level-dependent) response
Time Frame: 6-10 weeks
|
This outcome will be measured as changes (if any) of the BOLD responses of brain ROIs before, during and after their participation in the study procedures. |
6-10 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jay Hegde, PhD, Charlie Norwood VA Medical Center, Augusta, GA
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C4099-P
- I21RX004099-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.